Business Wire

CA-ARRCUS

26.2.2024 09:01:34 CET | Business Wire | Press release

Share
Arrcus Enhances ACE-AI Solution with New Platforms and Functionality to Deliver Lossless Connectivity Fabric for Next-Gen Distributed AI Workloads

Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, announces the enhancement of its ACE-AI platform to address the growing demand for unified networking fabric for distributed AI workloads.

As AI workloads become increasingly distributed, driven by economic considerations and application requirements, Arrcus ACE-AI is a platform designed to seamlessly network them across various locations and deliver applications at the edge, with high speed and lossless connectivity. The emerging federated learning model for AI allows multiple entities to collaboratively train a model with decentralized data. Training models may be executed in hyperscale environments while inference models may be executed at the edge for various use cases. Arrcus recognizes the need for a unified networking fabric that interconnects these workloads, regardless of where they may reside. Modern data center applications demand high throughput (400-800Gbps) and ultra-low latency (< 10μs per hop), and Arrcus ACE-AI meets these demands while minimizing CPU overhead.

"The future of AI lies in its ubiquity, and Arrcus has built the industry’s most flexible and intelligent fabric that connects and orchestrates distributed AI workloads,” said Shekar Ayyar, Chairman and CEO of Arrcus. “With the enhanced ACE-AI platform, we are giving enterprises and service providers the power to unlock the full potential of AI, across clouds, data centers, and the edge."

Emerging artificial intelligence, high-performance computing, and storage workloads pose new challenges for large-scale datacenter networking. Arrcus addresses these challenges by supporting new features that build a lossless Ethernet fabric, including RoCEv2, PFC, ECN, ETS, AR, Dynamic Load Balancing, and Global Load Balancing.

One of the significant challenges in achieving high-performance networking for AI workloads is the limitation of traditional TCP/IP stacks at such speeds due to their high CPU overhead. Arrcus addresses this challenge by incorporating RDMA (Remote Direct Memory Access) technology, which offloads transport communication tasks from the CPU to hardware, providing direct memory access for applications without involving the CPU. The second version of RDMA over Converged Ethernet (RoCE-v2) further enhances the protocol with UDP/IP headers with routing.

In addition to these feature enhancements, Arrcus is also pleased to announce support for new industry-leading platforms from Broadcom that are state-of-the-art 800G switching platforms – Tomahawk5, Jericho3, Ramon3 – in partnership with device manufacturers like Ufispace and Edgecore.

"Broadcom is very excited to collaborate with Arrcus to deliver industry-leading switching solutions that are optimized to meet the performance demands of next-generation AI workloads. Together, Arrcus and Broadcom are enabling customers to build high-performance, scalable, and intelligent data center networks,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.

Key features that make Arrcus the industry’s leading networking platform for AI:

  • High-Performance Networking for AI: Support for industry-leading hardware with Broadcom switches like Tomahawk5 and Jericho3-AI, RoCEv2, SmartNICs from NVIDIA and Intel, and enabling ultra-low latency (< 10μs per hop) and high throughput (400-800Gbps) required by modern AI applications.
  • Multi-Cloud Cost Optimization: Enhanced FlexMCN with Egress Cost Control (ECC) technology empowers users to analyze, allocate, and dynamically route traffic across clouds for optimal cost efficiency, reducing egress charges by up to 15%.
  • Automated 5G Network Slicing for AI: Integration of SRv6 Mobile User Plane (MUP) and Flex Algo enables automated delivery of AI applications with 5G network slicing, streamlining service deployment and resource allocation.
  • End-to-End Network Visibility with ArcIQ: New ArcIQ capabilities extend real-time network insights to user equipment, providing actionable data for proactive incident management.

With these latest capabilities and dedication to innovation, Arrcus is enabling organizations to break through the limitations of traditional networking and embrace the full potential of distributed AI. The enhanced ACE-AI platform signifies a pivotal step in building the intelligent fabric for the AI-powered future.

Additional Resources

About Arrcus

Arrcus was founded to enhance business efficiency through superior network connectivity. The Arrcus Connected Edge (ACE) platform offers best-in-class networking with the most flexible consumption model at the lowest total cost of ownership. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners and top-tier VCs. The company is headquartered in San Jose, California, with offices in Bangalore, India, and Tokyo, Japan. For more information, go to www.arrcus.com or follow @arrcusinc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226461853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye